Rank | Stock Exchange | Company | 2022 TWD, 100M |
2021 TWD, 100M |
YoY Growth% | 3-Year CAGR | Rank +/- |
---|---|---|---|---|---|---|---|
1 | Listed | Johnson Health Tech .Co., Ltd. (1736) | 338.4 | 307.2 | 10.1% | 10.1% | +0 |
2 | Listed | Lotus Pharmaceutical Co., Ltd. (1795) | 146.3 | 126.2 | 15.7% | 16.5% | +0 |
3 | OTC | Great Tree Pharmacy Co., Ltd. (6469) | 145.8 | 112.7 | 29.4% | 30.3% | +1 |
4 | Listed | Grape King Bio Ltd (1707) | 103.9 | 98.0 | 6.1% | 4.0% | +2 |
5 | OTC | Bora Pharmaceuticals Co., LTD. (6472) | 103.2 | 49.1 | 110.6% | 89.0% | +13 |
6 | OTC | TaiDoc Technology Corporation (4736) | 96.3 | 64.9 | 48.3% | 32.5% | +5 |
7 | Listed | China Chemical & Pharmaceutical Co., Ltd. (1701) | 82.6 | 79.8 | 3.5% | 1.2% | +2 |
8 | OTC | TCI Co., Ltd. (8436) | 74.3 | 85.8 | -13.4% | -8.1% | -1 |
9 | Listed | YungShin Global Holding Corporation (3705) | 73.1 | 78.1 | -6.3% | -3.7% | +1 |
10 | OTC | MedFirst Healthcare Services, Inc. (4175) | 72.3 | 65.4 | 10.6% | 10.8% | +3 |
11 | Listed | Excelsior Medical Co., Ltd. (4104) | 71.9 | 65.7 | 9.3% | 3.6% | +1 |
12 | Listed | Dyaco International Inc. (1598) | 71.3 | 117.5 | -39.3% | 6.9% | -9 |
13 | Listed | Pegavision Corporation (6491) | 63.2 | 56.0 | 13.0% | 23.5% | +2 |
14 | Listed | Standard Chemical & Pharmaceutical Co. Ltd. (1720) | 58.5 | 46.0 | 27.1% | 14.1% | +6 |
15 | OTC | Cowealth Medical Holding Co., Ltd. (4745) | 56.2 | 51.5 | 9.3% | 6.4% | +1 |
16 | OTC | TTY Biopharm Company Limited (4105) | 50.6 | 45.4 | 11.6% | 4.2% | - |
17 | OTC | St.Shine Optical Co.,Ltd. (1565) | 50.0 | 54.0 | -7.4% | -7.6% | -3 |
18 | OTC | Orient EuroPharma Co., Ltd. (4120) | 47.3 | 47.7 | -0.8% | -8.1% | +1 |
19 | OTC | Hi-Clearance Inc. (1788) | 46.9 | 36.8 | 27.3% | 13.1% | - |
20 | OTC | Synmosa Biopharma Corporation (4114) | 44.0 | 32.4 | 35.7% | 17.9% | - |
“Bio-Pharmaceuticals” ($89.09bn) closed the year with nearly $90 billion, “Medical Device R&D, Manufacturing” ($76.36bn) and “Workout Equipment & Health Supplement” ($67.17bn) sat on the second and the third.
Business focus / product types | Q1-Q4, 2022 (TWD, 100M) |
Q1-Q4, 2021 (TWD, 100M) |
2022 Growth rate % | Top 3 by Revenue 2022 | ||||
---|---|---|---|---|---|---|---|---|
No. of Company | Average Revenue | Total Revenue | No. of Company | Average Revenue | Total Revenue | |||
Bio-Pharmaceuticals | 75 | 11.9 | 890.9 | 69 | 11.7 | 806.0 | 10.5% | Lotus Pharma $14.63bn Bora Pharmaceuticals $10.32bn China Chemical & Pharmaceutical $8.26bn |
Medical Device, R&D, Manufacturing | 66 | 11.6 | 763.6 | 64 | 11.6 | 740.17 | 3.2% | TaiDoc $9.63bn Pegavision $6.32bn St.Shine Technology $5bn |
Workout Equipment & Health Supplement | 17 | 39.5 | 671.7 | 19 | 37.8 | 718.23 | -6.5% | Johnson Health Tech$33.84bn Grape King $10.39bn TCI $7.43bn |
Pharmacy & Distributor | 16 | 36.7 | 587.1 | 15 | 31.4 | 471.3 | 24.6% | Great Tree $14.58bn MedFirst $7.23bn COWealth $5.62bn |
Aesthetic Medicine & Beauty Care | 11 | 19.8 | 218.3 | 11 | 20.5 | 225.4 | -3.1% | Excelsior Medical $7.19bn Chlitina $4.07bn Jourdeness $2.79bn |
Agriculture & Agricultural Science | 7 | 18.4 | 129.1 | 10 | 21.1 | 210.68 | -38.7% | All Cosmos Biotech $3.71bn Mom Sun $3.37bn Huikwang $2.49bn |
APIs | 7 | 18.4 | 128.7 | 7 | 16.7 | 116.7 | 10.3% | Formosa Lab. $3.77bn ScinoPharm $3.26bn CCSB $2.12bn |
Genetic Testing & Wellness Check | 15 | 5.0 | 75.2 | 12 | 5.0 | 60.6 | 24.1% | Healthconn $1.55bn Bionet $980m Kim Forest $670m |
Total | 3464.4 | 16.2 | 3349.0 | 214 | 16.2 | 3.4% | 207 |
Top three by revenue are Johnson ($33.84bn), Lotus Pharma ($14.63bn) and Grape King Co. ($10.39bn).
Rank | Company | Revenue 2022 (QoQ Growth%) TWD, 100M |
||||
---|---|---|---|---|---|---|
Q1 | Q2 | Q3 | Q4 | Annually | ||
1 | Johnson Health Tech .Co., Ltd. (1736) | 75.2(3.7%) | 65.5(-0.6%) | 80.7(12.1%) | 117.0(20.7%) | 338.4(10.1%) |
2 | Lotus Pharmaceutical Co., Ltd. (1795) | 31.6(-4.9%) | 29.1(-16.0%) | 53.9(76.3%) | 31.7(13.2%) | 146.3(15.7%) |
3 | Grape King Bio Ltd (1707) | 20.5(4.1%) | 27.2(8.7%) | 24.9(3.7%) | 31.2(7.0%) | 103.9(6.1%) |
4 | China Chemical & Pharmaceutical Co., Ltd. (1701) | 19.5(-2.9%) | 20.9(2.1%) | 20.7(8.7%) | 21.6(6.4%) | 82.6(3.5%) |
5 | YungShin Global Holding Corporation (3705) | 19.5(9.9%) | 19.6(1.9%) | 16.2(-19.7%) | 17.8(-14.7%) | 73.1(-6.3%) |
6 | Excelsior Medical Co., Ltd. (4104) | 17.1(5.0%) | 16.7(5.8%) | 18.4(16.7%) | 19.6(9.9%) | 71.9(9.3%) |
7 | Dyaco International Inc. (1598) | 22.6(-41.0%) | 13.8(-50.5%) | 13.9(-42.9%) | 21.0(-22.2%) | 71.3(-39.3%) |
8 | Pegavision Corporation (6491) | 14.9(29.9%) | 14.1(2.4%) | 16.4(8.5%) | 17.8(14.3%) | 63.2(13.0%) |
9 | Standard Chemical & Pharmaceutical Co. Ltd. (1720) | 12.4(12.4%) | 14.8(28.9%) | 15.5(38.2%) | 15.8(28.4%) | 58.5(27.1%) |
10 | Chlitina Holding Limited (4137) | 10.3(-6.8%) | 7.6(-39.6%) | 12.2(-12.6%) | 10.5(-30.0%) | 40.7(-22.8%) |
11 | Formosa Laboratories, Inc. (4746) | 8.3(13.4%) | 8.4(0.6%) | 10.2(49.7%) | 10.7(20.2%) | 37.7(19.8%) |
12 | All Cosmos Bio-Tech Holding Corporation (4148) | 6.7(63.0%) | 9.2(63.5%) | 12.4(125.7%) | 8.8(30.7%) | 37.1(68.8%) |
13 | ScinoPharm Taiwan, Ltd. (1789) | 7.4(15.1%) | 8.1(7.7%) | 7.0(7.7%) | 10.2(41.2%) | 32.6(18.2%) |
14 | CHC Healthcare Group (4164) | 6.1(-5.4%) | 6.9(56.3%) | 8.2(70.7%) | 8.6(-2.2%) | 29.7(21.8%) |
15 | Sinphar Pharmaceutical Co.,Ltd. (1734) | 6.7(8.3%) | 7.1(17.8%) | 7.1(25.1%) | 7.6(18.9%) | 28.6(17.4%) |
16 | Jourdeness Group Limited (4190) | 6.4(-12.6%) | 6.6(-2.9%) | 6.7(6.3%) | 8.3(12.8%) | 27.9(0.8%) |
17 | Visco Vision Inc. (6782) | 6.5(42.1%) | 7.3(75.5%) | 7.1(47.6%) | 6.9(13.0%) | 27.8(41.5%) |
18 | Wellell Inc. (4106) | 6.0(2.5%) | 6.8(18.0%) | 6.9(15.6%) | 7.0(13.0%) | 26.7(12.3%) |
19 | Panion & Bf Biotech Inc. (1760) | 4.5(21.5%) | 8.1(52.8%) | 6.6(25.0%) | 4.7(0.7%) | 24.0(26.2%) |
20 | Adimmune Corporation (4142) | 0.5(661.8%) | 5.3(498.7%) | 10.9(44.3%) | 5.8(-26.3%) | 22.5(37.2%) |
Top three by revenue are Great Tree ($14.58bn), Bora Pharmaceuticals ($10.32bn) and TaiDoc ($9.63bn).
Rank | Company | Revenue 2022 (QoQ Growth%) TWD, 100M |
||||
---|---|---|---|---|---|---|
Q1 | Q2 | Q3 | Q4 | Annually | ||
1 | Great Tree Pharmacy Co., Ltd. (6469) | 32.0(28.6%) | 39.7(40.8%) | 36.2(24.4%) | 37.9(24.3%) | 145.8(29.4%) |
2 | Bora Pharmaceuticals Co., LTD. (6472) | 11.2(-18.2%) | 13.5(12.2%) | 27.1(128.9%) | 51.4(349.4%) | 103.2(110.6%) |
3 | TaiDoc Technology Corporation (4736) | 17.9(33.1%) | 36.3(116.2%) | 23.9(14.1%) | 18.1(32.3%) | 96.3(48.3%) |
4 | TCI Co., Ltd. (8436) | 16.6(-14.8%) | 18.5(-20.9%) | 20.6(-13.3%) | 18.6(-2.7%) | 74.3(-13.4%) |
5 | MedFirst Healthcare Services, Inc. (4175) | 16.1(7.6%) | 20.5(21.3%) | 17.1(6.7%) | 18.7(6.3%) | 72.3(10.6%) |
6 | Cowealth Medical Holding Co., Ltd. (4745) | 13.6(21.8%) | 14.0(-5.6%) | 14.7(16.9%) | 14.0(8.2%) | 56.2(9.3%) |
7 | TTY Biopharm Company Limited (4105) | 10.4(7.6%) | 11.6(11.7%) | 13.3(25.2%) | 15.3(4.4%) | 50.6(11.6%) |
8 | St.Shine Optical Co.,Ltd. (1565) | 13.5(3.0%) | 12.3(-8.8%) | 12.9(-9.7%) | 11.5(-13.7%) | 50.0(-7.4%) |
9 | Orient EuroPharma Co., Ltd. (4120) | 11.4(-5.9%) | 12.0(6.3%) | 11.0(-3.5%) | 12.8(0.2%) | 47.3(-0.8%) |
10 | Hi-Clearance Inc. (1788) | 9.8(11.3%) | 17.6(76.2%) | 9.9(9.8%) | 9.6(6.2%) | 46.9(27.3%) |
11 | Synmosa Biopharma Corporation (4114) | 9.7(26.6%) | 10.6(36.0%) | 11.1(42.3%) | 12.6(37.4%) | 44.0(35.7%) |
12 | Rossmax International Ltd. (4121) | 9.1(-4.2%) | 12.9(25.8%) | 10.8(15.8%) | 10.6(2.3%) | 43.4(10.1%) |
13 | ShareHope Medicine Co., Ltd. (8403) | 10.4(15.6%) | 11.2(18.4%) | 10.6(13.0%) | 9.2(-6.1%) | 41.4(10.0%) |
14 | Universal Vision Biotechnology Co., Ltd. (3218) | 8.4(36.9%) | 7.9(28.4%) | 9.1(36.1%) | 9.6(29.9%) | 34.9(32.8%) |
15 | Morn Sun Feed Mill Corp. (1240) | 7.6(18.0%) | 8.8(19.1%) | 8.3(7.6%) | 9.1(6.7%) | 33.7(12.4%) |
16 | Formosa Optical Technology Co.,Ltd. (5312) | 8.2(4.4%) | 7.2(20.6%) | 9.0(35.8%) | 9.0(3.2%) | 33.3(14.4%) |
17 | United Orthopedic Corporation (4129) | 7.4(18.1%) | 7.6(27.4%) | 7.4(20.3%) | 9.3(26.8%) | 31.7(23.3%) |
18 | BenQ Medical Technology Corporation (4116) | 6.2(85.5%) | 8.0(137.7%) | 7.6(100.6%) | 7.8(85.9%) | 29.5(101.5%) |
19 | PharmaEssentia Corporation (6446) | 2.5(157.7%) | 9.8(1026.9%) | 8.1(780.8%) | 8.4(121.8%) | 28.8(339.3%) |
20 | Huikwang Corporation (6508) | 6.3(20.4%) | 7.9(41.0%) | 8.0(63.2%) | 2.7(-47.9%) | 24.9(19.3%) |
Top three by revenue are Norbel ($4.2bn), We Can Medicines ($3.3bn, new to emerging stock market) and InnoCare Optoelectronics ($1.89bn).
Rank | Company | Revenue 2022 (QoQ Growth%) TWD, 100M |
||||
---|---|---|---|---|---|---|
Q1 | Q2 | Q3 | Q4 | Annually | ||
1 | Norbel Baby Co., Ltd (6844) | 9.7(6.9%) | 12.6(27.1%) | 9.8(4.6%) | 9.9(1.5%) | 42.0(10.2%) |
2 | WE CAN MEDICINES CO LTD (6929) | 9.7(6.9%) | 12.6(27.1%) | 9.8(4.6%) | 0.9(-308.7%) | 33.0(18.2%) |
3 | InnoCare Optoelectronics Corporation (6861) | 4.7(-11.7%) | 4.6(-8.4%) | 4.8(1.6%) | 4.8(9.7%) | 18.9(-2.8%) |
4 | DV Biomed Co., Ltd. (6539) | 4.9(-1.5%) | 4.3(11.2%) | 4.5(9.5%) | 5.0(-5.8%) | 18.7(2.4%) |
5 | Vizionfocus Inc. (4771) | 3.6(13.4%) | 4.0(13.3%) | 5.2(44.7%) | 5.5(42.5%) | 18.3(29.2%) |
6 | Healthconn Corp. (6665) | 3.5(28.7%) | 4.8(54.7%) | 3.9(-3.4%) | 3.3(-8.6%) | 15.5(15.1%) |
7 | CH Biotech R&D Co., Ltd. (6534) | 5.9(61.8%) | 7.0(127.5%) | 0.9(-30.9%) | 0.5(-74.8%) | 14.3(40.8%) |
8 | Taiwan Advanced Nanotech Inc. (6797) | 7.4(-2.6%) | 3.2(-8.3%) | 1.9(-54.2%) | 0.7(-81.9%) | 13.3(-31.2%) |
9 | Sunder Biomedical Tech. Co., Ltd. (4115) | 3.0(9.8%) | 2.7(1.5%) | 2.6(-11.0%) | 2.3(-27.1%) | 10.5(-7.6%) |
10 | Concord Medical Co., Ltd. (6518) | 2.0(10.0%) | 2.5(37.3%) | 2.2(24.7%) | 2.3(10.9%) | 8.9(20.4%) |
11 | Anxo Pharmaceutical Co., Ltd. (6677) | 1.8(-5.2%) | 1.9(-9.5%) | 2.4(23.2%) | 2.5(9.1%) | 8.6(4.4%) |
12 | Unicon Optical Co., Ltd. (4150) | 2.2(-8.6%) | 2.0(-2.3%) | 1.9(-9.3%) | 2.2(-11.4%) | 8.3(-8.1%) |
13 | TCM Biotech International Corp. (4169) | 1.7(0.8%) | 2.0(9.3%) | 2.0(27.7%) | 2.3(20.3%) | 8.0(14.3%) |
14 | Allied Biotech Corporation (1780) | 1.6(-9.6%) | 2.0(11.8%) | 2.0(30.0%) | 1.6(-5.4%) | 7.2(5.9%) |
15 | Amed Co., Ltd. (7575) | 1.5(15.7%) | 1.6(22.9%) | 1.8(31.0%) | 2.0(23.3%) | 6.9(23.3%) |
16 | Perfect Medical Industry Co., Ltd. (6543) | 1.6(-25.6%) | 1.7(-17.9%) | 1.7(9.4%) | 1.8(19.7%) | 6.8(-6.6%) |
17 | Kim Forest Enterprise Co., Ltd. (6645) | 1.2(44.6%) | 3.1(89.0%) | 1.4(-35.5%) | 1.0(-29.0%) | 6.7(10.6%) |
18 | Qing Song (6931) | -- | -- | -- | -- | 6.4(78.0%) |
19 | UBI Pharma Inc. (6562) | 1.5(22.4%) | 1.7(9.0%) | 1.9(7.4%) | 1.3(-34.0%) | 6.3(-1.6%) |
20 | A Plus Biotech (6918) | -- | -- | -- | 1.7(34.8%) | 6.2(13.6%) |
Source: MOPS; compiled by IBMI & RBMP